ICER’s Latest: A draft evidence report on new treatment for hypertrophic cardiomyopathy
On August 18, 2021, ICER released its draft evidence report, “Mavacamten for Hypertrophic Cardiomyopathy: Effectiveness and Value.” This is the first step in ICER’s process that, if the announced schedule holds, will lead to the release of final evidence report in...
LAST WORD: Treatments for Atopic Dermatitis
On August 17, 2021, ICER issued a Final Evidence Report on the clinical and cost-effectiveness of new treatments for atopic dermatitis (more commonly referred to as eczema). After following its typical process for gathering and reviewing data, ICER concluded that the...
LAST WORD: ICER’s Final Evidence Report on new Alzheimer’s treatment
On August 5, 2021, ICER issued its Final Evidence Report on aducanumab, a first-of-its-kind medication created to treat Alzheimer’s disease. Following its typical process for gathering information – which included the solicitation of public comments and a public...
RECOMMENDED READING: It is Time for Outcomes-Based Reimbursement for Biopharmaceuticals
By Robert Popovian & Mark Atalla July 16, 2021 Recently the U.S. Food and Drug Administration granted accelerated approval to aducanumab (Aduhelm), the first Alzheimer’s Disease treatment since 2003. While there has been significant discussion about aducanumab’s...
Happening Soon: Policy & Advocacy Webinar on ICER
On Monday, July 19th, the Pioneer Institute and the Pacific Research Institute (PRI) will host a virtual webinar, titled: Policy Measures on Drug Value: Does ICER’s Approach Improve Patient Access & Equity? The event will feature prominent experts in a discussion...
National Health Issues Survey Results: Trust Among Healthcare Stakeholder
Patients Rising – in coordination with Gravis Marketing, a leading market research and polling firm – recently conducted a survey to better understand American voters’ views on national health issues. The data from the survey – which was conducted in late April and...
National Health Issues Survey Results: European-Style Price Controls
Patients Rising – in coordination with Gravis Marketing, a leading market research and polling firm – recently conducted a survey to better understand American voters’ views on national health issues. The data from the survey – which was conducted in late April and...
VIDEO: ICER on the ‘value’ of treatments for Duchenne
In this space, we've talked a great deal about ICER's failure - often its refusal - to consider the needs and perspectives of patients when determining the value of a new drug or treatment. Patients Rising recently produced a short video about a meeting in 2019 about...
ICYMI: ICER’s Money Problem: A Self-Appointed ‘Drug Pricing Czar’
by Terry Wilcox & William Smith June 22, 2021 While the last year was very difficult for millions of Americans, it was also a period of rapid innovation as leaders in government and the private sector worked to combat a global pandemic. As a result, about half the...
National Health Issues Survey Results: Access & Affordability
Patients Rising - in coordination with Gravis Marketing, a leading market research and polling firm - recently conducted a survey to better understand American voters' views on various national health issues. The data from the survey - which was conducted in late...